Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Jay S. Wunder, Minji J. Lee, Junghyun Nam, Beatrice Y. Lau, Brendan C. Dickson, Dushanthi Pinnaduwage, Shelley B. Bull, Peter C. Ferguson, Andrew Seto, Nalan Gokgoz & Irene L. Andrulis. (2020) Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation. OncoImmunology 9:1.
Read now
Read now
Yeqi Sun, Wenwei Yu, Wenbin Guan, Lei Cai, Meng Qiao, Leizhen Zheng, Ruiqi Jiang, Ruifen Wang & Lifeng Wang. (2019)
Integrated assessment of PD-L1 expression and molecular classification facilitates therapy selection and prognosis prediction in gastric cancer. Cancer Management and Research 11, pages 6397-6410.
Read now
Read now
Articles from other publishers (31)
Satoshi Fukai, Shotaro Nakajima, Motonobu Saito, Katsuharu Saito, Koji Kase, Hiroshi Nakano, Takahiro Sato, Mei Sakuma, Akinao Kaneta, Hirokazu Okayama, Kosaku Mimura, Wataru Sakamoto, Zenichiro Saze, Tomoyuki Momma & Koji Kono. (2023) Down-regulation of stimulator of interferon genes (STING) expression and CD8+ T-cell infiltration depending on HER2 heterogeneity in HER2-positive gastric cancer. Gastric Cancer 26:6, pages 878-890.
Crossref
Crossref
Chloé Molimard, Fanny Dor, Alexis Overs, Franck Monnien, Grégoire Gessain, Loïs Kedochim, Flavia D'Angelo, Marine Abad, Morgane Heberle, Valentin Derangère, François Ghiringhelli, Lucine Vuitton, Séverine Valmary-Degano, Christophe Borg, Zaher Lakkis & Fréderic Bibeau. (2023) Evaluation of immune infiltrate according to the HER2 status in colorectal cancer. Digestive and Liver Disease.
Crossref
Crossref
Juan-Manuel Hernandez-Martinez, Rafael Rosell & Oscar Arrieta. (2023) Somatic and germline ATM variants in non-small-cell lung cancer: Therapeutic implications. Critical Reviews in Oncology/Hematology 188, pages 104058.
Crossref
Crossref
Hye-Ran Kim, Choong Won Seo, Sang Jun Han & Jongwan Kim. (2023) C4orf47 is a Novel Prognostic Biomarker and Correlates with Infiltrating Immune Cells in Hepatocellular Carcinoma. Biomedical Science Letters 29:1, pages 11-25.
Crossref
Crossref
Alejandro Alfaro, Daniel Zanabria, Alfredo Aguilar, Sergio Jimenez‑Solano, Alejandra Zevallos & Alejandro Alfaro. (2023) Gastric adenocarcinoma with high‑level microsatellite instability: A case report. Molecular and Clinical Oncology 18:3.
Crossref
Crossref
Qinyang Wang, Ziyang Mao, Wenyuan Li, Shumei Wang, Lei Wang, Lin Chen, Zhe Yang, Xiaolan Fu, Panpan Jiang, Yixue Bai, Longwen Xu, Shirong Zhang, Yuzhu Hou, Xiaohui Jia, Lili Jiang, Mengjie Liu, Guanjun Zhang, Yina Jiang & Hui Guo. (2022) Characteristics of the immunogenicity and tumor immune microenvironment in HER2-amplified lung adenocarcinoma. Frontiers in Immunology 13.
Crossref
Crossref
Han Yu, En Li, Sha Liu, ZuGuang Wu & FenFei Gao. (2022) Identification of Signature Genes in the PD-1 Relative Gastric Cancer Using a Combined Analysis of Gene Expression and Methylation Data. Journal of Oncology 2022, pages 1-30.
Crossref
Crossref
Zhenghang Wang, Xinyu Wang, Yu Xu, Jian Li, Xiaotian Zhang, Zhi Peng, Yajie Hu, Xinya Zhao, Kun Dong, Bei Zhang, Chan Gao, Xiaochen Zhao, Hui Chen, Jinping Cai, Yuezong Bai, Yu Sun & Lin Shen. (2022) Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma. BMC Medicine 20:1.
Crossref
Crossref
Nada Albarakati, Alaa Al‐Shareeda, Majed Ramadan, Batla Al‐Sowayan, Ola Negm & Taoufik Nedjadi. (2022)
Interaction between
HER2
and
ATM
predicts poor survival in bladder cancer patients
. Journal of Cellular and Molecular Medicine 26:19, pages 4959-4973.
Crossref
Crossref
Meiqi Li, Xianmei Zhong, Fukuan Du, Xu Wu, Mingxing Li, Yu Chen, Yueshui Zhao, Jing Shen, Zhongming Yang & Zhangang Xiao. (2022) Current Understanding and Future Perspectives on Hyperprogressive Disease Highlight the Tumor Microenvironment. The Journal of Clinical Pharmacology 62:9, pages 1059-1078.
Crossref
Crossref
Minsuk Kwon, Gahyun Kim, Ryul Kim, Kyu-Tae Kim, Seung Tae Kim, Simon Smith, Peter G S Mortimer, Jung Yong Hong, Arsene-Bienvenu Loembé, Itziar Irurzun-Arana, Loumpiana Koulai, Kyoung-Mee Kim, Won Ki Kang, Emma Dean, Woong-Yang Park & Jeeyun Lee. (2022) Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. Journal for ImmunoTherapy of Cancer 10:7, pages e005041.
Crossref
Crossref
Jie Shi, Xu Yang, Xinmei Wang, Yufeng Luo, Weixun Zhou, Hanhuan Luo, Zhaxi Bianba, Zhuoma Nima, Qian Wang, Han Wang, Ruiqian Liao, Quzhen Ciren, Mei Li & Junyi Pang. (2022) Prevalence of Epstein–Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer. BioMed Research International 2022, pages 1-11.
Crossref
Crossref
Kohei Shitara, Jaffer A. Ajani, Markus Moehler, Marcelo Garrido, Carlos Gallardo, Lin Shen, Kensei Yamaguchi, Lucjan Wyrwicz, Tomasz Skoczylas, Arinilda Campos Bragagnoli, Tianshu Liu, Mustapha Tehfe, Elena Elimova, Ricardo Bruges, Thomas Zander, Sergio de Azevedo, Ruben Kowalyszyn, Roberto Pazo-Cid, Michael Schenker, James M. Cleary, Patricio Yanez, Kynan Feeney, Michalis V. Karamouzis, Valerie Poulart, Ming Lei, Hong Xiao, Kaoru Kondo, Mingshun Li & Yelena Y. Janjigian. (2022) Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 603:7903, pages 942-948.
Crossref
Crossref
Hao Wang, Jing Wu, Ruoyu Ling, Fengping Li, Qingbin Yang, Jiayong He, Xuetao Lei, Chaorui Wu, Guofan Zhang, Boyang Zheng, Yanmei Peng, Yihao Zhang, Hao Chen, Gengtai Ye & Guoxin Li. (2022) Fibroblast-derived LPP as a biomarker for treatment response and therapeutic target in gastric cancer. Molecular Therapy - Oncolytics 24, pages 547-560.
Crossref
Crossref
Jayati Chakrabarti, Vivien Koh, Nina Steele, Jennifer Hawkins, Yoshiaki Ito, Juanita L. Merchant, Jiang Wang, Michael A. Helmrath, Syed A Ahmad, Jimmy Bok Yan So, Wei Peng Yong & Yana Zavros. (2021) Disruption of Her2-Induced PD-L1 Inhibits Tumor Cell Immune Evasion in Patient-Derived Gastric Cancer Organoids. Cancers 13:24, pages 6158.
Crossref
Crossref
Yinghui Hou & Guizhi Zhang. (2021) Identification of immune-infiltrating cell-related biomarkers in hepatocellular carcinoma based on gene co-expression network analysis. Diagnostic Pathology 16:1.
Crossref
Crossref
Xiang-Lei Yan, Qiu-Yun Luo, Su-Na Zhou, Wen-Tao Pan, Lin Zhang, Da-Jun Yang & Miao-Zhen Qiu. (2021) MicroRNA-375 reverses the expression of PD-L1 by inactivating the JAK2/STAT3 signaling pathways in gastric cancer. Clinics and Research in Hepatology and Gastroenterology 45:5, pages 101574.
Crossref
Crossref
Deqiang Wang, Ning Wang, Xiaoqin Li, Xiaofeng Chen, Bo Shen, Dongqin Zhu, Liuqing Zhu, Yaping Xu, Yangyang Yu & Yongqian Shu. (2021) Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia. Gastric Cancer 24:4, pages 823-834.
Crossref
Crossref
Deborah Blythe Doroshow, Sheena Bhalla, Mary Beth Beasley, Lynette M. Sholl, Keith M. Kerr, Sacha Gnjatic, Ignacio I. Wistuba, David L. Rimm, Ming Sound Tsao & Fred R. Hirsch. (2021) PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nature Reviews Clinical Oncology 18:6, pages 345-362.
Crossref
Crossref
Na Yang, Yanhua Wu, Meishan Jin, Zhifang Jia, Yueqi Wang, Donghui Cao, Lili Qin, Xueying Wang, Min Zheng, Xueyuan Cao & Jing Jiang. (2021) Microsatellite instability and Epstein-Barr virus combined with PD-L1 could serve as a potential strategy for predicting the prognosis and efficacy of postoperative chemotherapy in gastric cancer. PeerJ 9, pages e11481.
Crossref
Crossref
Mojun Zhu, Zhaohui Jin & Joleen M. Hubbard. (2021) Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. Cancers 13:4, pages 651.
Crossref
Crossref
Ran Duan, Xiaoqin Li, Dongqiang Zeng, Xiaofeng Chen, Bo Shen, Dongqin Zhu, Liuqing Zhu, Yangyang Yu & Deqiang Wang. (2021) Tumor Microenvironment Status Predicts the Efficacy of Postoperative Chemotherapy or Radiochemotherapy in Resected Gastric Cancer. Frontiers in Immunology 11.
Crossref
Crossref
Xiaoxia Jia, Ting Guo, Zhemin Li, Meng Zhang, Yi Feng, Bin Dong, Zhongwu Li, Ying Hu, Ziyu Li, Xiaofang Xing, Shuqin Jia & Jiafu Ji. (2021) Clinicopathological and Immunomicroenvironment Characteristics of Epstein–Barr Virus-Associated Gastric Cancer in a Chinese Population. Frontiers in Oncology 10.
Crossref
Crossref
Xuhui Bao, Xinjian Liu, Fang Li & Chuan-Yuan Li. (2020) Limited MOMP, ATM, and their roles in carcinogenesis and cancer treatment. Cell & Bioscience 10:1.
Crossref
Crossref
Maher A. Sughayer, Tamara Z. Dabbagh & Abdelkader H. Battah. (2020) PD-L1 Expression Is a Favorable Prognostic Marker in Gastric Carcinoma. Applied Immunohistochemistry & Molecular Morphology 28:10, pages 748-754.
Crossref
Crossref
M.J.M. van Velzen, S. Derks, N.C.T. van Grieken, N. Haj Mohammad & H.W.M. van Laarhoven. (2020) MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma. Cancer Treatment Reviews 86, pages 102024.
Crossref
Crossref
Ming Wu, Yadong Wang, Hang Liu, Jukun Song & Jie Ding. (2020) Genomic analysis and clinical implications of immune cell infiltration in gastric cancer. Bioscience Reports 40:5.
Crossref
Crossref
Shuzhen Tan, Dongpei Li & Xiao Zhu. (2020) Cancer immunotherapy: Pros, cons and beyond. Biomedicine & Pharmacotherapy 124, pages 109821.
Crossref
Crossref
Jukun Song, Zhenghao Deng, Jiaming Su, Dongbo Yuan, Jianguo Liu & Jianguo Zhu. (2019) Patterns of Immune Infiltration in HNC and Their Clinical Implications: A Gene Expression-Based Study. Frontiers in Oncology 9.
Crossref
Crossref
Jingyue Sun, Yao Long, Xin Peng, Desheng Xiao, Jianhua Zhou, Yongguang Tao & Shuang Liu. (2019) The survival analysis and oncogenic effects of CFP1 and 14-3-3 expression on gastric cancer. Cancer Cell International 19:1.
Crossref
Crossref
Mei Hua Jin & Do-Youn Oh. (2019) ATM in DNA repair in cancer. Pharmacology & Therapeutics 203, pages 107391.
Crossref
Crossref